The Department of the Army, on behalf of Operation Warp Speed, awarded Regeneron Pharmaceuticals Inc. a $5.565 billion firm fixed-price definitive contract to produce up to 1,250,000 doses of an emergency use authorized therapeutic in support of the national coronavirus disease 2019 (COVID-19) response. Funding is provided by the Department of the Army Acquisition Support Center Joint Project Executive Office for Chemical and Biological Defense. Regeneron will manufacture the doses at its facility in Sleepy Hollow, New York over an 18-month period ending July 2022. The contract is part of Operation Warp Speed's efforts to accelerate COVID-19 vaccine, therapeutic, and diagnostic development through public-private partnerships.
Generated 12/29/23, 2:37 PM